Systematic review: Sarcopenia in paediatric inflammatory bowel disease

• Published in: Clinical nutrition ESPEN Vol. 57; pp. 647 - 654
• Main Authors: Aljilani, Bayan, Tsintzas, Kostas, Jacques, Matthew, Radford, Shellie, Moran, Gordon W.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2023
• Subjects: Crohn's disease; Muscle mass; Muscle strength; Nutrition; Ulcerative colitis; Crohn's disease; Muscle strength; Nutrition; Muscle mass; Ulcerative colitis
• ISSN: 2405-4577; 2405-4577
• DOI: 10.1016/j.clnesp.2023.08.009

Low skeletal muscle mass (MM) and deteriorated function (sarcopenia) can be a frequent complication in paediatric inflammatory bowel disease (IBD). To conduct a systematic review of the paediatric IBD literature on skeletal muscle function and mass and identify interventions that could affect them. Systematic searches (EMBASE, Medline, Cochrane library central for registered control trials and Web of Science) were conducted using the terms ‘lean body mass’ (LM), ‘fat free mass' (FFM) or ‘MM’ and ‘IBD’. Fourteenth studies were included, presenting data from 439 Crohn's disease (CD), 139 ulcerative colitis (UC) and 2 IBD-unclassified participants compared with healthy matched or unmatched groups or reference populations. Six out of 14 studies reported lower LM, whilst 7 studies observed lower MM and FFM in CD patients compared to healthy controls. Research in UC patients reported lower LM in 3 studies, lower MM in 3 studies and lower FFM in 4 studies. Three prospective studies measured the impact of enteral feeding and showed improvement on disease activity and LM or FFM, while one retrospective study did not show any impact on LM. Despite the variety of experimental approaches and methods used to assess sarcopenia, most studies showed reduction in MM, LM and FFM in IBD. Nutritional intervention may have a positive effect on LM and FFM. Future research should focus on standardizing the terminology and methodologies used in assessing body composition and investigating sarcopenia in diseased and matched healthy control cohorts in adequately powered studies with a longitudinal design.